How it works:
Bendamustine is an alkylating agent that induces DNA damage in tumour cells, leading to cell death. It is particularly effective in lymphoproliferative diseases, especially in relapsed or resistant cases where standard therapies have failed.
Recommended for:
Patients with chronic lymphocytic leukaemia (CLL)
Individuals with indolent non-Hodgkin lymphoma
Cases of relapsed or refractory multiple myeloma
Those intolerant to first-line chemotherapy
Chronic lymphocytic leukaemia
Indolent non-Hodgkin lymphomas
Multiple myeloma in combination with prednisone
BENDIT is administered as an intravenous infusion under hospital supervision. Dosage and treatment cycles are determined by the physician based on diagnosis and patient tolerance. The powder must be reconstituted and diluted before use.
Known hypersensitivity to bendamustine or excipients
Severe bone marrow suppression
Active infections
Pregnancy and breastfeeding
Decompensated liver or kidney disease
Leukopenia, anaemia, thrombocytopenia
Nausea, vomiting, diarrhoea
Hair loss
Fatigue
Respiratory infections
Elevated liver enzymes
Infusion site reactions (redness, pain)
